EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors

Tianyu Xie, Wenbo Hu, Lin You, Xin Wang

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-10998-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Tianyu Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Liaoning University, Shenyang, 110036, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Protein Kinase Inhibitors, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the Education Department of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With cabozantinib as the precursor, a novel small molecule inhibitors of c-Met kinase with thieno [2,3-b] pyridine as the scaffold were designed, synthesized and evaluated for their biological activity against A549, Hela and MCF-7 cell lines. The in vitro activities of 16 compounds were tested by MTT method with cabozantinib as control drug. Most compounds had moderate to strong inhibitory activities on cells. Among them, compound 10 had the strongest inhibitory activity, which was superior to the lead compound cabozantinib. Its IC50 values for A549, Hela and MCF-7 cells were 0.005, 2.833 and 13.581 μM, respectively. The colony formation assay demonstrated that compound 10 significantly inhibited the colony formation of A549 cells and suppressed their growth in a concentration-dependent manner. The wound healing assay showed that compound 10 could effectively inhibit the migration of cancer cells compared to a blank control group. The AO/EB assay demonstrated that compound 10 possesses the capability to effectively trigger apoptosis in a concentration-dependent manner. The elementary structure-activity relationship, molecular docking and pharmacokinetics studies revealed the significance of thieno [2,3-b] pyridine derivatives in anti-tumor activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metProtein Kinase InhibitorsDrug DesignAntineoplastic AgentsThienopyridinesPyridinesHumansMolecular Docking SimulationStructure-Activity RelationshipApoptosisCell ProliferationCell Line, TumorCell MovementDrug Screening Assays, AntitumorMCF-7 CellsHeLa CellsA549 Cells

Stichwörter der Autor:innen

Anti-tumor activitySynthesisThieno [2,3-b] pyridinec-Met kinase inhibitor

Substanzen

Proto-Oncogene Proteins c-metProtein Kinase InhibitorsAntineoplastic AgentsThienopyridinesPyridines

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Liaoning University, Shenyang, 110036, China.
  • School of Pharmaceutical Sciences, Liaoning University, Shenyang, 110036, China. xinw521@163.com.
  • Liaoning Key Laboratory of New Drug Research & Development, Shenyang, 110036, China. xinw521@163.com.

Förderung

  • the Education Department of Liaoning Province

Zitieren

APA

Xie, T., Hu, W., You, L., & Wang, X. (2025). Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors. Molecular Diversity. https://doi.org/10.1007/s11030-024-10998-3

Vancouver

Xie T, Hu W, You L, Wang X. Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors. Molecular Diversity. 2025. doi:10.1007/s11030-024-10998-3

BibTeX
@article{Xie2025,
  author = {Xie, Tianyu and Hu, Wenbo and You, Lin and Wang, Xin},
  title = {Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-10998-3}
}
Kostenlos starten →